HSP90AB1 and neoplasm: At the Annual ASCO meeting in June 2012 [55], a small recent retrospective study evaluated pre-treatment tumor specimens for biomarkers such as HSP90 and HSP70 expression and other client proteins (using immunohistochemical staining) that can predict response to HSP90 inhibitors.